Psilocybin-assisted therapy is a leading area of psychedelic research. Psilocybin therapy has FDA breakthrough designation for treatment-resistant depression but isn’t yet FDA-approved. Legal access remains limited.
Research status
- FDA Breakthrough Therapy designation for TRD and major depression
- Phase 3 trials ongoing
- Potential FDA approval in coming years
- Promising results for depression, end-of-life anxiety, addiction
How it’s used in research
- Single or 2-3 high-dose sessions
- 6-8 hour dosing sessions with therapist support
- Preparation sessions before dosing
- Integration sessions after
- Total 8-12 session protocol typically
Legal access in US
Currently limited to:
- Clinical trials (clinicaltrials.gov)
- Oregon Psilocybin Services (state-legal program)
- Colorado natural medicine program (developing)
- Religious exemptions in some cases
Psilocybin remains Schedule I federally. Possession outside legal frameworks illegal.
Conditions in research
- Treatment-resistant depression (most data)
- Major depressive disorder
- End-of-life anxiety in cancer patients
- Alcohol use disorder
- Smoking cessation
- OCD (early stages)
- Eating disorders (early)
Effectiveness data
Promising but preliminary:
- Rapid effects from few sessions
- Effects can persist months
- Comparable or superior to standard antidepressants in some studies
- Long-term effectiveness still being studied
Risks and contraindications
- Psychosis history (contraindicated)
- Bipolar disorder concerns
- Cardiovascular conditions
- Difficult psychological experiences during dosing
- Need for proper screening and supervision
How to access
Legal options:
- Search clinicaltrials.gov for studies
- Oregon Psilocybin Services (must travel to Oregon)
- Wait for FDA approval (likely coming)
Frequently Asked Questions
Is psilocybin therapy legal?
In limited contexts (clinical trials, Oregon program). Otherwise illegal federally.
Will psilocybin become FDA-approved?
Likely in coming years for specific indications.
What’s it like?
Profound altered consciousness experience for several hours. Therapeutic context essential.
Is it addictive?
Not classically addictive. Different abuse profile than other drugs.
Can I just buy psilocybin?
Illegal outside specific legal contexts. Don’t recommend.
The bottom line on psilocybin therapy
Promising research with FDA breakthrough designation. Limited legal access currently. Approval likely coming. Don’t pursue outside legal frameworks.